[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641676":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":126,"collaborators":128,"id":132,"slug":133,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":10,"studyType":146,"phases":10,"briefSummary":147,"conditions":148,"keywords":10,"overallStatus":152,"whyStopped":10,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Fondazione Italiana Linfomi - ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma",null,"Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL) in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +\u002F- radiotherapy.\n\nPatients between third and fifth year of follow-up after the end of the first line treatment.",[13],"Drug: anthracycline containing regimen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","anthracycline containing regimen","Patients in complete remission after treatment with first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +\u002F- radiotherapy.",[9],[21],{"name":22,"affiliation":23,"role":24},"Silvia Franceschetti","U.O.C. Ematologia Ospedale Civile di Legnano - ASST Ovest Milanese - Legnano","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Iolanda Uffici Studi FIL","CONTACT","+390131033153","startup@filinf.it",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Uffici Studi FIL","+390599769910","gestionestudi@filinf.it",[36,52,65,78,90,103,113],{"facility":37,"status":10,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Clinica di Ematologia, AOU Ospedali Riuniti","Ancona","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],13.5103,43.60717,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":50,"phoneExt":10,"email":51},"Guido Gini","+390715964562","guido.gini@ospedaliriuniti.marche.it",{"facility":53,"status":10,"city":54,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Divisione di Oncologia e dei Tumori immuno-correlati - IRCCS Centro di Riferimento Oncologico di Aviano","Aviano",{"type":42,"coordinates":56},[57,58],12.59472,46.07056,{"lat":58,"lon":57},[61],{"name":62,"role":28,"phone":63,"phoneExt":10,"email":64},"Rosanna Ciancia","+390434659645","rciancia@cro.it",{"facility":66,"status":10,"city":67,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"U.O.C Ematologia - IRCCS Istituto Tumori Giovanni Paolo II","Bari",{"type":42,"coordinates":69},[70,71],16.86982,41.12066,{"lat":71,"lon":70},[74],{"name":75,"role":28,"phone":76,"phoneExt":10,"email":77},"Carla Minoia","+390805555414","carla.minoia1@gmail.com",{"facility":79,"status":10,"city":80,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"U.O.C. Ematologia Ospedale Civile di Legnano - ASST Ovest Milanese","Legnano",{"type":42,"coordinates":82},[83,84],8.91506,45.59788,{"lat":84,"lon":83},[87],{"name":22,"role":28,"phone":88,"phoneExt":10,"email":89},"+393333456770","silvia.franceschetti@asst-ovestmi.it",{"facility":91,"status":10,"city":92,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Ematologia - Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda","Milan",{"type":42,"coordinates":94},[95,96],12.59836,42.78235,{"lat":96,"lon":95},[99],{"name":100,"role":28,"phone":101,"phoneExt":10,"email":102},"Francesca Gaia Rossi","+390255033466","francescagaia.rossi@policlinico.mi.it",{"facility":104,"status":10,"city":92,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":105,"geoPoint":107,"contacts":108},"SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda",{"type":42,"coordinates":106},[95,96],{"lat":96,"lon":95},[109],{"name":110,"role":28,"phone":111,"phoneExt":10,"email":112},"Erika Meli","+390264442668","erika.meli@ospedaleniguarda.it",{"facility":114,"status":10,"city":115,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Ematologia - AOU Policlinico Giaccone","Palermo",{"type":42,"coordinates":117},[118,119],13.3636,38.1166,{"lat":119,"lon":118},[122],{"name":123,"role":28,"phone":124,"phoneExt":10,"email":125},"Salvatrice Mancuso","+390916554505","salvatrice.mancuso@unipa.it",{"type":127,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[129],{"name":130,"class":131},"Associazione Italiana contro Leucemie, Linfomi e Mieloma","UNKNOWN","100641676","neurocognitive-assessment-in-long-term-survivors-of-lymphoma-100641676",false,"NCT07652476","Neurocognitive Assessment in Long-Term Survivors of Lymphoma","Neurocognitive Assessment in Long-Term Survivors of Lymphoma: An Observational Study by the Fondazione Italiana Linfomi (FIL)","FIL_LymDeCo","Inclusion Criteria:\n\n* Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL).\n* Patients in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +\u002F- radiotherapy.\n* Age ≥ 25 and ≤ 55 at enrollment.\n* Patients between third and fifth year of follow-up after the end of the first line treatment.\n* Absence of signs or symptoms of disease relapse.\n\nExclusion Criteria:\n\n* Patients with CNS disease localization.\n* Patients that received brain\u002Fneuroaxis radiotherapy.\n* Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.","ALL","25 Years","55 Years",{"count":144,"type":145},100,"ESTIMATED","OBSERVATIONAL","This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse.\n\nThe assessment of neurocognitive functioning will be performed through a panel of tests, both self-administered and individually administered (about 1 hour). The administration of these neuropsychological tests should be done according to a standardized and predefined order. If available, according to local practice, a neuropsychologist may be involved in test administration and in the evaluation of the results.\n\nBased on its observational nature, no treatment change or modification or additional exams or visits will be required because of being enrolled in this study.",[149,150,151],"Classic Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)","Primary Mediastinal B Cell Lymphoma","NOT_YET_RECRUITING","2026-06-17",{"date":155,"type":156},"2026-06-22","ACTUAL",{"date":158,"type":145},"2026-09",{"date":160,"type":145},"2028-03",{"name":5,"class":6},7]